Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

The Utility of Liquid Biopsy in Central Nervous System Malignancies.

TitleThe Utility of Liquid Biopsy in Central Nervous System Malignancies.
Publication TypeJournal Article
Year of Publication2018
AuthorsNevel KS, Wilcox JA, Robell LJ, Umemura Y
JournalCurr Oncol Rep
Volume20
Issue8
Pagination60
Date Published2018 06 06
ISSN1534-6269
KeywordsBiomarkers, Tumor, Central Nervous System Neoplasms, Circulating MicroRNA, Circulating Tumor DNA, Humans, Liquid Biopsy, Meningeal Neoplasms, Neoplasm Metastasis, Neoplastic Cells, Circulating
Abstract

PURPOSE OF REVIEW: Liquid biopsy is a sampling of tumor cells or tumor nucleotides from biofluids. This review explores the roles of liquid biopsy for evaluation and management of patients with primary and metastatic CNS malignancies.

RECENT FINDINGS: Circulating tumor cell (CTC) detection has emerged as a relatively sensitive and specific tool for diagnosing leptomeningeal metastases. Circulating tumor DNA (ctDNA) detection can effectively demonstrate genetic markup of CNS tumors in the cerebrospinal fluid, though its role in managing CNS malignancies is less well-defined. The value of micro RNA (miRNA) detection in CNS malignancies is unclear at this time. Current standard clinical tools for the diagnosis and monitoring of CNS malignancies have limitations, and liquid biopsy may help address clinical practice and knowledge gaps. Liquid biopsy offers exciting potential for the diagnosis, prognosis, and treatment of CNS malignancies, but each modality needs to be studied in large prospective trials to better define their use.

DOI10.1007/s11912-018-0706-x
Alternate JournalCurr Oncol Rep
PubMed ID29876874

Weill Cornell Medicine Neurology 525 E. 68th St.
PO Box 117
New York, NY 10065 Phone: (212) 746-6575